Return to homepagePandemic Pact

Residual pulmonary fibrosis and lung capacity in survivors of SARS-CoV-2

  • Funded by National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)
  • Total publications:0 publications

Grant number: COV20_00401

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)

  • Principal Investigator

    José Ramón Blanco Ramos

  • Research Location

    Spain

  • Lead Research Institution

    FUNDACION RIOJA SALUD

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older), Older adults (65 and older)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

After the severe acute respiratory syndrome coronavirus (SARS-CoV) epidemic (2003/2003), many of the survivors developed residual pulmonary fibrosis (PF). Autopsies of these SARS patients showed the presence of pulmonary fibrosis at different stages of infection. Risk of PF was higher in older people, and was correlated with clinical severity and disease duration. On the other hand, lung biopsies showed dysregulation of the inflammatory response, the serum levels of certain pro-inflammatory cytokines being especially elevated. Furthermore, SARS-CoV infection induces an overactivation of the TGF-􀑛 pathway leading to pulmonary fibrosis.